Intraventricular HER2 CAR T-cell therapy may be an option for patients with HER2+ breast cancer and brain metastasis. Read More ›

In the phase 3 OlympiAD trial, treatment with olaparib significantly improved progression-free survival and reduced the risk for disease progression or death compared with standard chemotherapy in women with HER2-negative, BRCA-mutated metastatic breast cancer. Read More ›

PD-L1 positivity in all cells in patients with breast cancer may be a useful prognostic marker based on a recent meta-analysis. Read More ›

A new analysis shows that there is an ongoing, steady risk for metastatic or distant recurrence of cancer from years 5 to 20 among women with estrogen receptor–positive breast cancer. Read More ›

After accounting for the benefit of pertuzumab, investigators found that >6 cycles of docetaxel did not significantly improve progression-free or overall survival in patients with HER2-positive, metastatic breast cancer. Read More ›

Abemaciclib offers a new option for women with HR-positive, HER2-negative advanced metastatic breast cancer. Read More ›

Five-year analysis of the phase 3 ALTTO trial showed no decided benefit to dual HER2 blockade over single-agent HER2-targeted therapy for the treatment of HER2-positive early-stage breast cancer. However, an indication for dual HER2 blockade use in HER2-positive, estrogen receptor–negative tumors is a possibility. Read More ›

A modest reduction in the risk for invasive breast cancer was achieved by adding a second HER2-targeted agent to the treatment regimen for women with early-stage HER2+ breast cancer. The results suggest that the strategy may be appropriate in women at highest risk for recurrence. Read More ›

Single-agent pembrolizumab produced durable responses in women with metastatic triple-negative breast cancer who have received prior chemotherapy for metastatic disease. Read More ›

A 9-week course of trastuzumab as adjuvant therapy in women with hormone receptor–positive, early-stage breast cancer can maintain efficacy and reduce toxicity compared with the standard 1-year course of trastuzumab. Read More ›